Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Japan Rhabdomyosarcoma Study Group
- Target Recruit Count
- 41
- Registration Number
- NCT00245089
- Locations
- π―π΅
Anjo Kosei Hosptial, Anjo, Aichi, Japan
π―π΅National Hospital Orgnization Nagoya Medical Center, Nagoya, Aichi, Japan
π―π΅National Kyushu Cancer Center, Fukuoka-shi, Fukuoka, Japan
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Japan Rhabdomyosarcoma Study Group
- Target Recruit Count
- 32
- Registration Number
- NCT00245141
- Locations
- π―π΅
Ibaraki Children's Hospital, Mito-shi, Ibaraki, Japan
π―π΅Shiga University of Medical Science, Otsu-shi, Shiga, Japan
π―π΅Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 7
- Registration Number
- NCT00245115
- Locations
- πΊπΈ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 44
- Registration Number
- NCT00242996
- Locations
- πΊπΈ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors
- Conditions
- Bone Marrow SuppressionBrain and Central Nervous System TumorsDrug/Agent Toxicity by Tissue/OrganLong-term Effects Secondary to Cancer Therapy in Children
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00238173
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
- Conditions
- Lymphoma
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 59
- Registration Number
- NCT00238368
- Locations
- πΊπΈ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Procedure: BiopsyProcedure: Serum CollectionProcedure: Urine CollectionDrug: GemcitabineDrug: DoxorubicinDrug: CapecitabineDrug: VinorelbineDrug: Cyclophosphamide
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 80
- Registration Number
- NCT00235235
- Locations
- πΊπΈ
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
πΊπΈBaylor College of Medicine - Methodist Breast Center, Houston, Texas, United States
πΊπΈArnett Cancer Care, Lafayette, Indiana, United States
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: carmustineDrug: cyclophosphamideDrug: etoposideDrug: melphalanProcedure: autologous-autologous tandem hematopoietic stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 98
- Registration Number
- NCT00233987
- Locations
- πΊπΈ
Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States
πΊπΈAssociates in Womens Health, PA - North Review, Wichita, Kansas, United States
πΊπΈCancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
- Conditions
- Recurrent Breast CancerStage IV Ovarian Epithelial CancerRecurrent Non-small Cell Lung CancerStage IV Breast CancerHER2-positive Breast CancerRecurrent Ovarian Germ Cell TumorRecurrent Ovarian Epithelial CancerStage IV Non-small Cell Lung CancerStage IV Ovarian Germ Cell Tumor
- Interventions
- Drug: ex vivo-expanded HER2-specific T cellsBiological: denileukin diftitoxDrug: cyclophosphamideOther: flow cytometryOther: immunoenzyme technique
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 8
- Registration Number
- NCT00228358
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
- Conditions
- Hodgkin Disease
- Interventions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 45
- Registration Number
- NCT00225173
- Locations
- πΊπΈ
Stanford University Medical Center, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.